Advertisement
Research Article| Volume 16, ISSUE 7, e508-e513, July 2012

The epidemiology and clinical characteristics of respiratory syncytial virus infection in children at a public pediatric referral hospital in Mexico

Open ArchivePublished:April 23, 2012DOI:https://doi.org/10.1016/j.ijid.2012.03.001

      Summary

      Objectives

      The aim of this study was to determine the epidemiological and clinical characteristics of children with respiratory syncytial virus (RSV) treated at a public referral children's hospital in Mexico.

      Methods

      We reviewed RSV infection in patients aged 0–18 years who were treated at Hospital Infantil from January 2004 to December 2008.

      Results

      During the 5 years, 2797 samples were tested for respiratory viruses; 356 samples were positive for any virus, including 266 (74.7%) positive for RSV. Complete clinical information was available for 205 RSV patients. The mean age was 22 months, and 33.7% of the infections were nosocomially acquired. Hospitalization occurred in 187 children. Of 14 deaths, nine were directly attributed to RSV infection. During the study, RSV infections were seen throughout the year, predominating in the colder months. Of the 205 patients, 79.0% (162/205) had an underlying disease. Congenital heart disease was found in 30.2% (49/162), including three children (33.3%) who died of RSV. Thirty-three patients (16.1%) with RSV required mechanical ventilation. None of the children with RSV received palivizumab or ribavirin.

      Conclusions

      RSV caused high hospitalization rates and admission to intensive care units, especially among those with underlying illnesses and young infants. The data presented here will be useful for strategies to improve outcomes in children at risk of complications.

      Keywords

      1. Introduction

      Respiratory syncytial virus (RSV) is an important cause of viral lower respiratory tract infections in infants and children worldwide,
      • Nair H.
      • Nokes D.J.
      • Gessner B.D.
      • Dherani M.
      • Madhi S.A.
      • Singleton R.J.
      • et al.
      Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.
      • Stensballe L.G.
      An epidemiological study of respiratory syncytial virus associated hospitalizations in Denmark.
      and it is a significant pathogen in immune-compromised hosts and those with underlying cardiopulmonary diseases.
      • Pezzotti P.
      • Mantovani J.
      • Benincori N.
      • Mucchino E.
      • Di Lallo D.
      Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy.
      • Blanchard S.S.
      • Gerrek M.
      • Siegel C.
      • Czinn S.J.
      Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: case report and discussion regarding need of routine prophylaxis.
      • Ebbert J.O.
      • Limper A.H.
      Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome.
      Globally, the RSV burden is estimated at 64 million cases and 160 000 deaths annually;

      World Health Organization. Respiratory syncytial virus and parainfluenza viruses. Geneva: WHO; 2009. Available at: http://www.who.int/vaccine_research/diseases/ari/en/index2.html (accessed September 24, 2010).

      for those younger than 1 year old, the estimated RSV mortality rate was shown to be more than nine times that of influenza.
      • Thompson W.W.
      • Shay D.K.
      • Weintraub E.
      • Brammer L.
      • Cox N.
      • Anderson L.J.
      • et al.
      Mortality associated with influenza and respiratory syncytial virus in the United States.
      A recent prospective study of Kenyan infants and children hospitalized with severe pneumonia showed that RSV was the predominant pathogen isolated,
      • Berkley J.A.
      • Munywoki P.
      • Ngama M.
      • Kazungu S.
      • Abwao J.
      • Bett A.
      • et al.
      Viral etiology of severe pneumonia among Kenyan infants and children.
      and other studies have shown similar findings.
      • Noyola D.E.
      • Rodriguez-Moreno G.
      • Sanchez-Alvarado J.
      • Martinez-Wagner R.
      • Ochoa-Zavala R.
      Viral etiology of lower respiratory tract infections in hospitalized children in Mexico.
      • Light M.
      • Bauman J.
      • Mavunda K.
      • Malinoski F.
      • Eggleston M.
      Correlation between respiratory syncytial virus (RSV) test data and hospitalization of children with lower respiratory tract illness in Florida.
      RSV is transmitted by contact with infectious droplets. An incidence of nosocomial RSV infection of 6% (90 of 1568 documented RSV infections) was reported in a prospective multicenter surveillance study done in Germany covering six consecutive seasons from 1999 to 2005.
      • Simon A.
      • Muller A.
      • Khurana K.
      • Engelhart S.
      • Exner M.
      • Schildgen O.
      • et al.
      Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection—results from a prospective multicenter German surveillance study.
      Some investigators suggest that the true incidence of nosocomial RSV may be underestimated.
      • Diez D.J.
      • Ridao L.M.
      • Ubeda S.I.
      • Ballester S.A.
      [Incidence and cost of hospitalizations for bronchiolitis and respiratory syncytial virus infections in the autonomous community of Valencia in Spain (2001 and 2002)].
      In a recent study in a general hospital in Mexico, investigators found that RSV was responsible for 26% of confirmed respiratory infections among those tested for RSV in children younger than 5 years old.
      • Noyola D.E.
      • Zuviri-Gonzalez A.
      • Castro-García J.A.
      • Ochoa-Zavala J.R.
      Impact of respiratory syncytial virus on hospital admissions in children younger than 3 years of age.
      To better understand the contribution of RSV infection to the morbidity and mortality of very high risk children, we analyzed the clinical characteristics and epidemiology of RSV in pediatric patients aged 0–18 years and their outcomes at Hospital Infantil de México Federico Gómez (Hospital Infantil) during 2004–2008.

      2. Materials and methods

      2.1 Setting

      Hospital Infantil is a public, multi-specialty, teaching and referral hospital with 290 beds for children aged 0–18 years located in Mexico City. Patients admitted to Hospital Infantil are those with complex diseases who require highly specialized care and come from Mexico City, the surrounding communities, and other more distant cities. Mexico City has an elevation of 2240 meters (7350 feet) above sea level, and the cooler months are from November through February. Patients with RSV are allocated single-bed rooms if available, or are placed in rooms with other patients with RSV. Hospital Infantil is one of the three most important teaching pediatric centers in Mexico City, however other care centers for children who require hospitalization also exist in the city. During the study years, the average annual discharge was 6356 patients, and bed occupancy was 85.2%.

      2.2 Study population and design

      We conducted a retrospective, observational study that included all consecutive patients aged 0–18 years at Hospital Infantil with respiratory symptoms and a positive antigen test for RSV using an indirect immunofluorescence antibody assay (IFA) during the study period of January 1, 2004 through December 31, 2008. By using the microbiology laboratory registry, we constructed a list of patients with respiratory infections for whom respiratory virus testing was required. Patients who were positive for RSV and for whom complete demographic data and medical information were available were included in the study. Medical information required included underlying disease, date of onset of disease to determine whether community- or hospital-acquired, length of hospital stay, wards in which they were hospitalized, clinical presentation, laboratory information, development of complications, illness severity, and deaths related to RSV infection. Information was collected regarding initial hospital site of care where respiratory samples were obtained and signs and symptoms on presentation, such as cough, rhinorrhea, bronchospasm, respiratory distress, apnea, cyanosis, and fever (≥38 °C). The severity of the clinical status was determined on the basis of whether admission to the intensive care unit was required and whether mechanical ventilation was needed. The decision regarding tracheal intubation was determined by the patients’ clinical status using the Silverman–Andersen score.
      • Silverman W.A.
      • Andersen D.H.
      A controlled clinical trial of effects of water mist on obstructive respiratory signs, death rate and necropsy findings among premature infants.
      RSV infection was considered nosocomial when the symptoms appeared on inpatient day 6 or later and if patients were readmitted with RSV less than 5 days after discharge and the first admission was for a non-RSV illness.
      • Hall C.B.
      The nosocomial spread of respiratory syncytial viral infections.

      American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker C, Kimberlin DW, Long SS, editors. Red book: 2009 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2009. p. 560–9.

      The study was approved by the Institutional Research Ethics Committee of Hospital Infantil.

      2.3 Sample collection and laboratory processing

      All children with symptoms of viral upper or lower respiratory tract infection attending Hospital Infantil had nasal swabs taken for the study of the respiratory virus as part of the standard of care. Rayon-tipped, aluminum-shafted swabs (Copan Italia S.p.a., Brescia, Italy) were used to collect nasal secretion samples, and bronchial aspirate was collected from those who were intubated. To identify RSV antigen in the respiratory samples, an IFA was performed (Light Diagnostics Respiratory Panel I Viral Screening and Identification IFA, Millipore (UK) Ltd) for the detection of parainfluenza virus types 1, 2, and 3, adenovirus, influenza types A and B, and RSV. Metapneumovirus and rhinovirus were not tested for. The assay was conducted in accordance with the manufacturer's instructions. The samples were obtained at the point of patient care (i.e., the emergency department, intensive care units, or other inpatient wards).

      2.4 Statistical methods

      Frequencies and comparisons of variables in the information obtained were analyzed using SPSS version 16. Descriptive statistics such as means and proportions were used to report origin, month of diagnosis, age, hospitalization ward, length of hospitalization, underlying illnesses, and severity of RSV infection.

      3. Results

      3.1 Study population

      A total of 2797 respiratory secretion samples were collected from the same number of patients, and these samples were studied in the microbiology laboratory of Hospital Infantil. From 356 samples that were positive for any respiratory viral agent, RSV was the most frequently isolated virus (266, 74.7%; Table 1). For our study we selected 205 patients for whom complete clinical data were available. We had no clinical information on 61 patients (22.9%) with RSV infection, so they were excluded from further study. Occasionally, children who do not receive routine care at Hospital Infantil are tested in this hospital's laboratories. These children often do not have medical records at this hospital, and it is likely that the children in the group that we excluded for lack of clinical information were such children.
      Table 1Viruses identified in respiratory infections at Hospital Infantil, 2004–2008
      VirusYearTotal
      20042005200620072008
      RSV4957238948266
      Parainfluenza 321418429
      Influenza A13021025
      Parainfluenza 22103713
      Parainfluenza 17010311
      Adenovirus220419
      Influenza B010113
      Total positive63652813664356
      Total negative2153663917746952441
      RSV, respiratory syncytial virus.

      3.2 Demographic characteristics

      The demographic and clinical characteristics of the 205 study subjects are shown in Table 2. The mean age of the patients was 22 months (range 0.6–180 months), and the median and the mode were 9 and 2 months, respectively. Eighty percent (164/205) of the patients infected with RSV were aged ≤24 months (Figure 1), and 50% were aged between 4 months (first quartile) and 21 months (third quartile). There were 105 girls and 100 boys. Of the 205 patients, 187 (91.2%) required hospitalization. Most of the patients (162/205, 79.0%) with RSV infections had an underlying disease, such as congenital heart disease (CHD; 49/162, 30.2%) and neoplastic diseases (28/162, 17.3%).
      Table 2Demographics and clinical characteristics of 205 patients with RSV infections at Hospital Infantil, 2004–2008
      Demographics and characteristicsResult, % (n)
      Mean age in months22 (range 0.6–180)
      Females51.2% (105)
      Underlying disease
      Some individuals had more than one underlying disease; total of 175 diseases.
      79.0% (162 patients with 175 diseases
      Denominator for underlying diseases subgroup=175 diseases.
      )
       Congenital heart disease28% (49)
       Neoplastic disease16% (28)
       Down syndrome9.1% (16)
       Bronchopulmonary dysplasia5.7% (10)
       Hepatopathy5.7% (10)
       Neurological diseases5.7% (10)
       Gastrointestinal disease4.6% (8)
       Congenital malformation – non-cardiac4% (7)
       Steroid use4% (7)
       HIV3.4% (6)
       Endocrine/metabolic2.9% (5)
       Infectious process – non-viral2.9% (5)
       Hematological – non-malignant2.3% (4)
       Pulmonary disease2.3% (4)
       Cystic fibrosis1.1% (2)
       Renal disease1.1% (2)
       Other
      Other diseases included a case of cervical lymphangioma and a case of craniosynostosis.
      1.1% (2)
      Community-acquired RSV infection66.3% (136)
      Nosocomially-acquired RSV infection
      A nosocomial RSV infection in our study was defined by onset of symptoms on or after day 6 of hospitalization.
      33.7% (69)
      Point of care when diagnostic sample taken
       Emergency room54.6% (112)
       General ward26.3% (54)
       Surgery7.3% (15)
       Oncology5.4% (11)
       Intensive care unit3.4% (7)
       Neonatal intensive care unit2.9% (6)
      Diagnostic sample type
       Nasal swab83.9% (172)
       Bronchial aspirate16.1% (33)
      Respiratory symptoms
       Cough80% (164)
       Fever55.6% (114)
       Respiratory distress47.8% (98)
       Rhinorrhea43.9% (90)
       Apnea3.9% (8)
        <3 months100% (8)
      Diagnosis
       Pneumonia65.3% (134)
       Bronchiolitis13.2% (27)
       Pharyngitis12.7% (26)
       Other8.8% (18)
      Antibiotics upon admission67.3% (138)
      a Some individuals had more than one underlying disease; total of 175 diseases.
      b Denominator for underlying diseases subgroup = 175 diseases.
      c Other diseases included a case of cervical lymphangioma and a case of craniosynostosis.
      d A nosocomial RSV infection in our study was defined by onset of symptoms on or after day 6 of hospitalization.
      Figure thumbnail gr1
      Figure 1Age distribution of confirmed RSV infection cases at Hospital Infantil, 2004–2008 (n = 205).
      In most other reports, RSV has been seen in younger patients (i.e., those younger than 6 months);
      • Stensballe L.G.
      An epidemiological study of respiratory syncytial virus associated hospitalizations in Denmark.
      • Wahab A.A.
      • Dawod S.T.
      • Raman H.M.
      Clinical characteristics of respiratory syncytial virus infection in hospitalized healthy infants and young children in Qatar.
      the mean age in our study was higher, but other measures of central tendencies (median and mode) were lower than the mean because of the asymmetric age distribution of our sample population (positively skewed). Thus, more than 60% were older than 6 months, in whom hospitalization was most likely due to underlying illnesses. Among patients with RSV infection, 12.8% were born at less than 34 weeks of gestation, 11.7% were born between 34 and 37 weeks of gestation, and 75.5% were full-term infants. Most of the patients (82.4%) originated from Mexico City and surrounding areas and the rest (17.6%) were from other regions of Mexico.

      3.3 Epidemiology of RSV infections at Hospital Infantil

      Most of the samples (112/205, 54.6%) were collected while the patients were in the emergency room; the rest were collected from the general pediatric wards (54/205, 26.3%), surgical wards (15/205, 7.3%), oncology (11/205, 5.4%), intensive care unit (7/205, 3.4%), and neonatal intensive care unit (6/205, 2.9%). Most cases occurred in the fall (147/266, 55.3%), with 31.6% (84/266) in winter, 6.0% (16/266) in spring, and 7.1% (19/266) in summer. During the 5 years of the study, RSV infections were less common during the warmer months of the year (March to June), and peaked during the cooler months (August to March), changing year to year (Figure 2). Approximately a third (69/205, 33.7%) of the RSV infections were acquired in the hospital, and the rest were acquired in the community (136/205, 66.3%). The duration of hospitalization of patients with community-acquired infection ranged from 1 to 70 days (median 7 days). Of those inpatients, 49.3% (67/136) stayed less than 7 days, 27.9% (38/136) stayed 7–14 days, and 22.8% (31/136) stayed more than 14 days.
      Figure thumbnail gr2
      Figure 2Seasonal and monthly distribution of subjects tested (n = 2797) for respiratory viruses and RSV detection (n = 266) from 2004 to 2008 in Hospital Infantil.

      3.4 Clinical presentation and severity

      At presentation, the patients had cough (164/205, 80%), fever (114/205, 55.6%), respiratory distress (98/205, 47.8%), and rhinorrhea (90/205, 43.9%). The most frequent findings by lung auscultation were crackles (98/205, 47.8%), rattles (117/205, 57.1%), and wheezing (55/205, 26.8%). Eight patients (3.9%) had apnea. The most frequent clinical diagnoses were pneumonia (134/205, 65.3%), bronchiolitis (27/205, 13.2%), and pharyngitis (26/205, 12.7%). Other less frequent diagnoses were atypical pneumonia (8/205, 3.9%), rhinitis (5/205, 2.4%), and otitis (3/205, 1.5%). Of the 111 patients with chest radiographs, 25.2% (28/111) had interstitial infiltrates, 23.4% (26/111) had perihilar infiltrates, and 18.0% (20/111) had lung overdistention. Other radiology findings were bilateral infiltrates, consolidation, infiltrates in both bases, and atelectasis. Most of the patients (138/205, 67.3%) received antibiotics upon admission to the hospital. The most frequently used antibiotics for suspected bacterial pneumonia were ampicillin (22.4%), cefuroxime (20.2%), and cefotaxime plus dicloxacillin (13.0%). Other antibiotics used were clarithromycin, cefepime plus amikacin, and amoxicillin/clavulanic acid.
      In terms of the illness severity, 33/205 (16.1%) required mechanical ventilation and 14 of these children (42.4%) died. Nine deaths occurred at <30 days after testing positive for RSV and were possibly related to the RSV infection, giving a global mortality rate of 4.4% (9/205); the five other deaths occurred ≥30 days after the initial diagnosis of RSV and these deaths were not directly attributed to RSV. The mean age of the patients who died was 12 months. Five of the patients who died had a nosocomially-acquired RSV infection (Table 3). No prophylaxis with palivizumab or treatment with ribavirin was used in any of the patients in this study.
      Table 3Deaths in RSV-infected children at Hospital Infantil, 2004–2008
      Patient
      Patients 1–9 died within 30 days of the diagnosis of RSV infection; patients 10–14 died 30 days or more after the diagnosis of RSV infection.
      Age (months)SexWardDate of diagnosisSource of RSVUnderlying diagnosisInfectious syndromeICU admission
      1168MICU01/08/2004CommunityDown syndromePneumoniaYes
      22MICU03/01/2004NosocomialBPDPneumoniaYes
      34FIDU12/15/2004NosocomialBPDPneumoniaNo
      45FER02/01/2006CommunityCHDPneumoniaNo
      512MICU10/05/2006CommunityPreviously healthyPneumoniaYes
      626FER03/15/2007CommunityCHDPneumoniaNo
      7180FER09/17/2007CommunitySLE and high dose steroid usePneumoniaNo
      87FICU10/17/2007CommunityCHDPneumoniaYes
      921FER10/21/2008CommunityWest syndromePneumoniaNo
      105MER11/27/2008CommunityNeuropathyPneumoniaNo
      113FER08/29/2007CommunityCHDPneumoniaNo
      125FICU02/23/2004NosocomialCHDPneumoniaYes
      134MER03/09/2004NosocomialPreviously healthyPneumoniaNo
      144MER11/15/2007NosocomialDown syndromePneumoniaNo
      RSV, respiratory syncytial virus; ICU, intensive care unit; ER, emergency room; IDU, infectious disease unit; M, male; F, female; BPD, bronchopulmonary dysplasia; CHD, congenital heart disease; SLE, systemic lupus erythematosus.
      a Patients 1–9 died within 30 days of the diagnosis of RSV infection; patients 10–14 died 30 days or more after the diagnosis of RSV infection.

      4. Discussion

      RSV was the most frequent viral pathogen found in respiratory samples tested using IFA in Hospital Infantil during the 5-year study period from 2004 to 2008, accounting for 74.7% of all the respiratory viruses isolated from patients with respiratory tract infections. Most of the children with RSV required hospitalization, and more than three quarters were younger than 2 years old. In contrast to other published RSV epidemiologic studies,
      • Stensballe L.G.
      An epidemiological study of respiratory syncytial virus associated hospitalizations in Denmark.
      • Noyola D.E.
      • Zuviri-Gonzalez A.
      • Castro-García J.A.
      • Ochoa-Zavala J.R.
      Impact of respiratory syncytial virus on hospital admissions in children younger than 3 years of age.
      • García C.G.
      • Bhore R.
      • Soriano-Fallas A.
      • Trost M.
      • Chason R.
      • Ramilo O.
      • et al.
      Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis.
      the patients we describe here were at high risk for RSV complications and were not receiving RSV prophylaxis. As a result, many of them were hospitalized. The most frequent underlying diseases among these hospitalized children were CHD, malignancies, and bronchopulmonary disease (BPD). Most of the patients had respiratory symptoms; some were severe and the patients required admission to the intensive care unit and assisted mechanical ventilation. Death was attributed directly to RSV infection in two thirds of the patients who died.
      It is well established that most infants are infected with RSV by 2 years of age,
      • Simoes E.A.
      Respiratory syncytial virus.
      and that the majority of these infections are symptomatic.
      • Tristram D.A.
      • Welliver R.C.
      Respiratory syncytial virus.
      Lower respiratory tract infections occur in up to one third of symptomatic infections necessitating hospitalization.
      • Tristram D.A.
      • Welliver R.C.
      Respiratory syncytial virus.
      The lower the age of these children, the higher the need for hospitalization.
      • Boyce T.G.
      • Mellen B.G.
      • Mitchel E.F.
      • Wright P.F.
      • Griffin M.R.
      Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid.
      Mortality from RSV infection is low in healthy children, but this is increased in children with cardiac disease, chronic respiratory disease, or immune deficiencies.
      • Thorburn K.
      Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection.
      At Hospital Infantil, 80% (n = 164) of the participants were younger than 2 years of age. In this group, almost three quarters (n = 121, 73.8%) had an underlying disease. The mortality due to RSV was higher in this group of children with underlying diseases (n = 8, 6.6%) than in those without underlying diseases (n = 1, 2.3%).
      In a study conducted by García et al.
      • García C.G.
      • Bhore R.
      • Soriano-Fallas A.
      • Trost M.
      • Chason R.
      • Ramilo O.
      • et al.
      Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis.
      in Texas among children less than 2 years of age with bronchiolitis, it was found that 2840 children had RSV and that 770 (27.1%) of those children had risk factors such as prematurity, cardiopulmonary pathologies, congenital syndromes, immunodeficiencies, and neuromuscular disorders. Three children with RSV died (0.1%), and two of them (0.26%) had risk factors (one with congenital heart disease and the other had Moebious syndrome). The authors indicated that lower RSV infections in children with risk factors were most likely due to anti-RSV prophylaxis; however, the author pointed out that better prevention strategies are necessary.
      Another study conducted by Noyola et al.
      • Noyola D.E.
      • Zuviri-Gonzalez A.
      • Castro-García J.A.
      • Ochoa-Zavala J.R.
      Impact of respiratory syncytial virus on hospital admissions in children younger than 3 years of age.
      studied respiratory infections among children less than 3 years of age in a public general hospital in Mexico during a period of 24 months. RSV was detected in 153 of 616 subjects with respiratory infections. From this group, 120 (78.4%) infants with RSV infections were previously healthy and 33 (21.6%) had one or more underlying disorders. There were no deaths during the study period. Hospital Infantil is one of the few public and tertiary pediatric centers in Mexico, and children at high risk of RSV morbidity and mortality concentrate at this institution. Infected children often need frequent and/or prolonged hospitalization and access to intensive care units and mechanical ventilation, which increases the morbidity from RSV. In this hospital, as in most public hospitals in Mexico, high-risk children who qualify for seasonal RSV prophylaxis do not currently receive palivizumab, and if infected with RSV they do not receive specific antivirals for RSV. Some published studies have reported children with RSV at risk for complications separately from healthy children,
      • Pezzotti P.
      • Mantovani J.
      • Benincori N.
      • Mucchino E.
      • Di Lallo D.
      Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy.
      • Blanchard S.S.
      • Gerrek M.
      • Siegel C.
      • Czinn S.J.
      Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: case report and discussion regarding need of routine prophylaxis.
      • Simon A.
      • Muller A.
      • Khurana K.
      • Engelhart S.
      • Exner M.
      • Schildgen O.
      • et al.
      Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection—results from a prospective multicenter German surveillance study.
      • García C.G.
      • Bhore R.
      • Soriano-Fallas A.
      • Trost M.
      • Chason R.
      • Ramilo O.
      • et al.
      Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis.
      and in others, the populations of healthy and at-risk children have been different to our study sample;
      • Berkley J.A.
      • Munywoki P.
      • Ngama M.
      • Kazungu S.
      • Abwao J.
      • Bett A.
      • et al.
      Viral etiology of severe pneumonia among Kenyan infants and children.
      • Diez D.J.
      • Ridao L.M.
      • Ubeda S.I.
      • Ballester S.A.
      [Incidence and cost of hospitalizations for bronchiolitis and respiratory syncytial virus infections in the autonomous community of Valencia in Spain (2001 and 2002)].
      • Noyola D.E.
      • Zuviri-Gonzalez A.
      • Castro-García J.A.
      • Ochoa-Zavala J.R.
      Impact of respiratory syncytial virus on hospital admissions in children younger than 3 years of age.
      therefore, our results are different due to the characteristics of the patients attending Hospital Infantil.
      One third of the RSV cases were acquired in the hospital. Nosocomial RSV infection in immunocompromised patients and those with CHD places them at high risk for severe, often fatal, RSV pneumonia.
      • Pezzotti P.
      • Mantovani J.
      • Benincori N.
      • Mucchino E.
      • Di Lallo D.
      Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy.
      • Thompson W.W.
      • Shay D.K.
      • Weintraub E.
      • Brammer L.
      • Cox N.
      • Anderson L.J.
      • et al.
      Mortality associated with influenza and respiratory syncytial virus in the United States.
      In addition, the risk of death is higher among children who acquire an RSV infection nosocomially than among those who acquire RSV in the community.
      • Blanchard S.S.
      • Gerrek M.
      • Siegel C.
      • Czinn S.J.
      Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: case report and discussion regarding need of routine prophylaxis.
      • Ebbert J.O.
      • Limper A.H.
      Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome.
      When implementing targeted interventions based on education of health care providers and adherence to infection prevention and control measures, the transmission rates decrease substantially.
      • Macartney K.K.
      • Gorelick M.H.
      • Manning M.L.
      • Hodinka R.L.
      • Bell L.M.
      Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control.
      • Lavergne V.
      • Ghannoum M.
      • Weiss K.
      • Roy J.
      • Beliveau C.
      Successful prevention of respiratory syncytial virus nosocomial transmission following an enhanced seasonal infection control program.
      RSV can survive on hard surfaces for up to 7 h and remains detectable on cloth, paper, and stethoscopes after 30 min.
      • Lavergne V.
      • Ghannoum M.
      • Weiss K.
      • Roy J.
      • Beliveau C.
      Successful prevention of respiratory syncytial virus nosocomial transmission following an enhanced seasonal infection control program.
      Factors associated with nosocomial acquisition of RSV infection are young age, underlying or chronic disease, long hospitalization, crowding, suboptimal staff-to-patient ratio, and lack of good infection prevention practices such as isolation precautions, good hand hygiene, and visitation policies.

      World Health Organization. Respiratory syncytial virus and parainfluenza viruses. Geneva: WHO; 2009. Available at: http://www.who.int/vaccine_research/diseases/ari/en/index2.html (accessed September 24, 2010).

      • Macartney K.K.
      • Gorelick M.H.
      • Manning M.L.
      • Hodinka R.L.
      • Bell L.M.
      Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control.
      • Lavergne V.
      • Ghannoum M.
      • Weiss K.
      • Roy J.
      • Beliveau C.
      Successful prevention of respiratory syncytial virus nosocomial transmission following an enhanced seasonal infection control program.
      We observed that most of these factors were present at Hospital Infantil during the study period. The most important measure for preventing infections is avoiding disease transmission and acquisition in the first place.
      • Hall C.B.
      Nosocomial respiratory syncytial virus infections: the “Cold War” has not ended.
      Infection prevention strategies are recommended to curb the transmission of respiratory viruses, including RSV. To lessen the rates of transmission during hospitalization, an institution-wide program must be established, preferably as part of an infection prevention and control program.
      • Lavergne V.
      • Ghannoum M.
      • Weiss K.
      • Roy J.
      • Beliveau C.
      Successful prevention of respiratory syncytial virus nosocomial transmission following an enhanced seasonal infection control program.
      • Groothuis J.
      • Bauman J.
      • Malinoski F.
      • Eggleston M.
      Strategies for prevention of RSV nosocomial infection.
      • Simon A.
      • Khurana K.
      • Wilkesmann A.
      • Muller A.
      • Engelhart S.
      • Exner M.
      • et al.
      Nosocomial respiratory syncytial virus infection: impact of prospective surveillance and targeted infection control.
      Guidelines recommend rapid patient diagnosis, compliance with acceptable hand hygiene techniques, and cohorting of patients and staff.

      American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker C, Kimberlin DW, Long SS, editors. Red book: 2009 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2009. p. 560–9.

      • Groothuis J.
      • Bauman J.
      • Malinoski F.
      • Eggleston M.
      Strategies for prevention of RSV nosocomial infection.
      Emphasis on health care provider compliance with optimum prevention practices during epidemics must be the goal to decrease rates of nosocomial infection.
      • Bont L.
      Nosocomial RSV infection control and outbreak management.
      One fifth of the hospitalized children with RSV at Hospital Infantil acquired the infection in the community and required mechanical ventilation. The mortality was higher in those with underlying diseases. During the 5-year study period, none of the infants and children who qualified for prophylaxis received palivizumab. Reasons for not using this pharmacologic intervention were its cost and other competing needs at Hospital Infantil, which is a resource-limited public hospital. In children with risk factors for severe RSV, palivizumab, a humanized mouse antibody, is recommended during the RSV season.

      American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker C, Kimberlin DW, Long SS, editors. Red book: 2009 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2009. p. 560–9.

      • Tsitsikas D.A.
      • Oakervee H.
      • Cavenagh J.D.
      • Gribben J.
      • Agrawal S.G.
      • Mattes F.M.
      Treatment of respiratory syncytial virus infection in haematopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience.
      Like other immune-mediated factors, palivizumab functions by targeting the highly conserved RSV F glycoprotein, inhibiting viral entry into host cells.
      • Empey K.M.
      • Peebles Jr., R.S.
      • Kolls J.K.
      Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.
      Factors that lead to effective results in the use of palivizumab are safety and tolerability, ease of administration, and lack of interference with normal vaccinations. With the exception of a few reports
      • Tsitsikas D.A.
      • Oakervee H.
      • Cavenagh J.D.
      • Gribben J.
      • Agrawal S.G.
      • Mattes F.M.
      Treatment of respiratory syncytial virus infection in haematopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience.
      • Boeckh M.
      • Berrey M.M.
      • Bowden R.A.
      • Crawford S.W.
      • Balsley J.
      • Corey L.
      Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.
      • Ghosh S.
      • Champlin R.E.
      • Englund J.
      • Giralt S.A.
      • Rolston K.
      • Raad I.
      • et al.
      Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin.
      in which therapy with palivizumab was successful in treatment, the primary indication in the use of this monoclonal antibody is for RSV prevention.
      • Empey K.M.
      • Peebles Jr., R.S.
      • Kolls J.K.
      Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.
      • Kimpen J.L.
      Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing.
      Vaccination provides the best way to elicit a durable and effective immune response to an infection. Unfortunately, to date, no effective RSV vaccine has been developed. Until a good vaccine is available, measures to prevent infection during epidemics include the use of palivizumab and optimum infection prevention and control practices.
      • Fretzayas A.
      • Moustaki M.
      The challenges of RSV vaccines. Where do we stand?.
      At Hospital Infantil, patients with RSV received hydration and nutritional and respiratory supportive care, including the use of bronchodilators and steroids, following current and official guidelines, such as those of the American Academy of Pediatrics.

      American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker C, Kimberlin DW, Long SS, editors. Red book: 2009 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2009. p. 560–9.

      Treatment of RSV bronchiolitis, in addition to supportive care, must be individualized and provided early in the illness;
      • Checchia P.
      Identification and management of severe respiratory syncytial virus.
      use of bronchodilators and steroids is common during the care of RSV bronchiolitis. According to some experts and based on the results of a meta-analysis of published studies, bronchodilators such as racemic epinephrine, salbutamol, and ipratropium bromide, despite transient relief of respiratory distress, have no beneficial effects on acute RSV bronchiolitis.
      • Langley J.M.
      • Smith M.B.
      • LeBlanc J.C.
      • Joudrey H.
      • Ojah C.R.
      • Pianosi P.
      Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076].
      • Flores G.
      • Horwitz R.I.
      Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis.
      More studies are needed for conclusive recommendations. Likewise, steroid use early in the course of the infection has demonstrated benefits,
      • Schuh S.
      • Coates A.L.
      • Binnie R.
      • Allin T.
      • Goia C.
      • Corey M.
      • et al.
      Efficacy of oral dexamethasone in outpatients with acute bronchiolitis.
      • Bentur L.
      • Shoseyov D.
      • Feigenbaum D.
      • Gorichovsky Y.
      • Bibi H.
      Dexamethasone inhalations in RSV bronchiolitis: a double-blind, placebo-controlled study.
      but support for conclusive recommendations are also needed. Systematic improvement in supportive measures, such as respiratory support therapy, hydration, and nutrition, can produce substantial results. Cost-effective actions such as these are amenable to hospitals like Hospital Infantil. These actions may positively affect survival among very young children and those with underlying diseases.
      Hospital Infantil is one of three main hospitals in Mexico City for referral of highly complex pediatric disease cases, including those children with CHD, other congenital malformations, prematurity, and immunodeficiency. Therefore, it was not surprising to find that the most frequent underlying diseases among children hospitalized for RSV infection at Hospital Infantil were CHD, malignancies, and BPD. Children with those pathologies have a more severe RSV course and often need hospital care for the complications of the underlying pathology and the RSV infection.
      • Pezzotti P.
      • Mantovani J.
      • Benincori N.
      • Mucchino E.
      • Di Lallo D.
      Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy.
      • Thompson W.W.
      • Shay D.K.
      • Weintraub E.
      • Brammer L.
      • Cox N.
      • Anderson L.J.
      • et al.
      Mortality associated with influenza and respiratory syncytial virus in the United States.
      • Thorburn K.
      Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection.
      Also, these patients often require prolonged hospitalization, thus increasing the chance of acquiring infections nosocomially, such as RSV infections during RSV epidemics.
      • Hall C.B.
      The nosocomial spread of respiratory syncytial viral infections.
      Our study provides a better understanding of the yearly RSV epidemics and their contribution to the burden of respiratory infections among our patients at Hospital Infantil. Data on the seasonality of RSV and institutional care and prevention guidelines are particularly useful to health care providers for the management of patients at high risk of morbidity and mortality and to administrators for planning and implementing cost-effective policies to satisfy the needs of such patients, especially during epidemics. These guidelines work better when adapted to the available resources and unique needs at each site; implementation and compliance with these guidelines during the RSV season has been shown to make a difference in outcomes.
      • McCarthy C.A.
      • Hall C.B.
      Respiratory syncytial virus: concerns and control.
      Our findings, which were shared with the leaders of Hospital Infantil, initiated improvements in planning and implementing infection prevention and control strategies, especially for high-risk patients. As a direct result of our study, we are currently working on best care and prevention practice guidelines for respiratory infections at Hospital Infantil.
      Limitations of our study include its retrospective nature, the fact that we obtained a relatively low number of positive RSV results, and that complete information was not available for almost 25% of patients with RSV infections. Weaknesses of retrospective studies are that they rely on existing medical records that were collected for reasons other than research, and when specific information is absent, this is difficult to resolve. Also, it is difficult to control biases and confounders in this type of study. However, retrospective studies are inexpensive, use existing records, and more importantly can generate hypotheses that can be tested prospectively.
      • Hess D.R.
      Retrospective studies and chart reviews.
      Our study had a relatively small number of positive respiratory virus results, including RSV, and we speculate on several possible reasons. First, we included the reports of all respiratory samples regardless of when in the duration of illness the sample was collected. The threshold for obtaining a respiratory sample in our patients was low, because most of them had serious risk factors for complications of RSV infection. In other studies
      • Berkley J.A.
      • Munywoki P.
      • Ngama M.
      • Kazungu S.
      • Abwao J.
      • Bett A.
      • et al.
      Viral etiology of severe pneumonia among Kenyan infants and children.
      • Noyola D.E.
      • Zuviri-Gonzalez A.
      • Castro-García J.A.
      • Ochoa-Zavala J.R.
      Impact of respiratory syncytial virus on hospital admissions in children younger than 3 years of age.
      a case definition was used for the collection of respiratory samples. Second, we used only one laboratory method (IFA) for testing viral pathogens. The sensitivity of IFA is less than other methods such as PCR and serology, which have been used in other studies.
      • Bezerra P.G.
      • Britto M.C.
      • Correia J.B.
      • Duarte Mdo C.
      • Fonceca A.M.
      • Rose K.
      • et al.
      Viral and atypical bacterial detection in acute respiratory infection in children under five years.
      • Stensballe L.G.
      • Kofoed P.E.
      • Nante E.J.
      • Sambo M.
      • Jensen I.P.
      • Aaby P.
      Duration of secretory IgM and IgA antibodies to respiratory syncytial virus in a community study in Guinea-Bissau.
      And finally, obtaining more than one sample improves the success of getting a positive result. Improving the stated limitations in the study design, sample collection, and laboratory methods will increase the success in ascertaining positive laboratory results. Reviewing the work flow at Hospital Infantil, it was estimated that most of the patients we lacked information for were not admitted to the hospital, and we concluded that their clinical course must have been mild. Even when including patients with incomplete information into our calculations, the hospitalization rate was still high (187 of 266 children with positive RSV tests). The participants discussed in this report consist of patients who had a confirmed RSV infection and most of them were admitted to Hospital Infantil. As such, almost 80% of the patients had an underlying disease and therefore a much higher risk of complications. Also, because Hospital Infantil is a referral center for patients with complex diseases, the epidemiology and outcomes may be different in a hospital treating children with less complex diseases.
      • Hall C.B.
      • Weinberg G.A.
      • Iwane M.K.
      • Blumkin A.K.
      • Edwards K.M.
      • Staat M.A.
      • et al.
      The burden of respiratory syncytial virus infection in young children.
      However, we think that since the conditions at Hospital Infantil may mirror other hospitals of similar socioeconomic background and referral patterns, the information presented here will be useful in guiding the formulation of local policies for the treatment and prevention of RSV and, most importantly, for allocating institutional resources, including personnel, for best care and prevention of RSV during epidemic seasons.

      Acknowledgements

      We thank the staff of Hospital Infantil de México for the excellent care of the children reported in this manuscript and David Galloway for excellent editorial advice. This study was supported by the Department of Pediatric Infectious Diseases of Hospital Infantil de México Federico Gómez and the American Lebanese Syrian Associated Charities (ALSAC).
      Funding: This study was supported by the Department of Pediatric Infectious Diseases of Hospital Infantil de México and the American Lebanese Syrian Associated Charities (ALSAC).
      Ethical approval: The study was approved by the Institutional Research Ethics Committee of Hospital Infantil.
      Conflict of interest: None of the authors of this report have any conflicts of interest.

      References

        • Nair H.
        • Nokes D.J.
        • Gessner B.D.
        • Dherani M.
        • Madhi S.A.
        • Singleton R.J.
        • et al.
        Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.
        Lancet. 2010; 375: 1545-1555
        • Stensballe L.G.
        An epidemiological study of respiratory syncytial virus associated hospitalizations in Denmark.
        Respir Res. 2002; 3: S34-S39
        • Pezzotti P.
        • Mantovani J.
        • Benincori N.
        • Mucchino E.
        • Di Lallo D.
        Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy.
        BMC Pediatr. 2009; 9: 56
        • Blanchard S.S.
        • Gerrek M.
        • Siegel C.
        • Czinn S.J.
        Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: case report and discussion regarding need of routine prophylaxis.
        Pediatr Transplant. 2006; 10: 826-829
        • Ebbert J.O.
        • Limper A.H.
        Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome.
        Respiration. 2005; 72: 263-269
      1. World Health Organization. Respiratory syncytial virus and parainfluenza viruses. Geneva: WHO; 2009. Available at: http://www.who.int/vaccine_research/diseases/ari/en/index2.html (accessed September 24, 2010).

        • Thompson W.W.
        • Shay D.K.
        • Weintraub E.
        • Brammer L.
        • Cox N.
        • Anderson L.J.
        • et al.
        Mortality associated with influenza and respiratory syncytial virus in the United States.
        JAMA. 2003; 289: 179-186
        • Berkley J.A.
        • Munywoki P.
        • Ngama M.
        • Kazungu S.
        • Abwao J.
        • Bett A.
        • et al.
        Viral etiology of severe pneumonia among Kenyan infants and children.
        JAMA. 2010; 303: 2051-2057
        • Noyola D.E.
        • Rodriguez-Moreno G.
        • Sanchez-Alvarado J.
        • Martinez-Wagner R.
        • Ochoa-Zavala R.
        Viral etiology of lower respiratory tract infections in hospitalized children in Mexico.
        Pediatr Infect Dis J. 2004; 23: 118-123
        • Light M.
        • Bauman J.
        • Mavunda K.
        • Malinoski F.
        • Eggleston M.
        Correlation between respiratory syncytial virus (RSV) test data and hospitalization of children with lower respiratory tract illness in Florida.
        Pediatr Infect Dis J. 2008; 27: 512-518
        • Simon A.
        • Muller A.
        • Khurana K.
        • Engelhart S.
        • Exner M.
        • Schildgen O.
        • et al.
        Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection—results from a prospective multicenter German surveillance study.
        Int J Hyg Environ Health. 2008; 211: 241-250
        • Diez D.J.
        • Ridao L.M.
        • Ubeda S.I.
        • Ballester S.A.
        [Incidence and cost of hospitalizations for bronchiolitis and respiratory syncytial virus infections in the autonomous community of Valencia in Spain (2001 and 2002)].
        An Pediatr (Barc). 2006; 65: 325-330
        • Noyola D.E.
        • Zuviri-Gonzalez A.
        • Castro-García J.A.
        • Ochoa-Zavala J.R.
        Impact of respiratory syncytial virus on hospital admissions in children younger than 3 years of age.
        J Infect. 2007; 54: 180-184
        • Silverman W.A.
        • Andersen D.H.
        A controlled clinical trial of effects of water mist on obstructive respiratory signs, death rate and necropsy findings among premature infants.
        Pediatrics. 1956; 17: 1-10
        • Hall C.B.
        The nosocomial spread of respiratory syncytial viral infections.
        Annu Rev Med. 1983; 34: 311-319
      2. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker C, Kimberlin DW, Long SS, editors. Red book: 2009 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2009. p. 560–9.

        • Wahab A.A.
        • Dawod S.T.
        • Raman H.M.
        Clinical characteristics of respiratory syncytial virus infection in hospitalized healthy infants and young children in Qatar.
        J Trop Pediatr. 2001; 47: 363-366
        • García C.G.
        • Bhore R.
        • Soriano-Fallas A.
        • Trost M.
        • Chason R.
        • Ramilo O.
        • et al.
        Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis.
        Pediatrics. 2010; 126: e1453-e1460
        • Simoes E.A.
        Respiratory syncytial virus.
        Lancet. 1999; 354: 847-852
        • Tristram D.A.
        • Welliver R.C.
        Respiratory syncytial virus.
        in: Long S.S. Pickering L.K. Prober C.G. Principles and practices of pediatric infectious diseases. 2nd ed. Churchill Livingstone, Philadelphia, PA2003: 1140-1148
        • Boyce T.G.
        • Mellen B.G.
        • Mitchel E.F.
        • Wright P.F.
        • Griffin M.R.
        Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid.
        J Pediatr. 2000; 137: 865-870
        • Thorburn K.
        Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection.
        Arch Dis Child. 2009; 94: 99-103
        • Macartney K.K.
        • Gorelick M.H.
        • Manning M.L.
        • Hodinka R.L.
        • Bell L.M.
        Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control.
        Pediatrics. 2000; 106: 520-526
        • Lavergne V.
        • Ghannoum M.
        • Weiss K.
        • Roy J.
        • Beliveau C.
        Successful prevention of respiratory syncytial virus nosocomial transmission following an enhanced seasonal infection control program.
        Bone Marrow Transplant. 2011; 46: 137-142
        • Hall C.B.
        Nosocomial respiratory syncytial virus infections: the “Cold War” has not ended.
        Clin Infect Dis. 2000; 31: 590-596
        • Groothuis J.
        • Bauman J.
        • Malinoski F.
        • Eggleston M.
        Strategies for prevention of RSV nosocomial infection.
        J Perinatol. 2008; 28: 319-323
        • Simon A.
        • Khurana K.
        • Wilkesmann A.
        • Muller A.
        • Engelhart S.
        • Exner M.
        • et al.
        Nosocomial respiratory syncytial virus infection: impact of prospective surveillance and targeted infection control.
        Int J Hyg Environ Health. 2006; 209: 317-324
        • Bont L.
        Nosocomial RSV infection control and outbreak management.
        Paediatr Respir Rev. 2009; 10: 16-17
        • Tsitsikas D.A.
        • Oakervee H.
        • Cavenagh J.D.
        • Gribben J.
        • Agrawal S.G.
        • Mattes F.M.
        Treatment of respiratory syncytial virus infection in haematopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience.
        Br J Haematol. 2009; 146: 574-576
        • Empey K.M.
        • Peebles Jr., R.S.
        • Kolls J.K.
        Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.
        Clin Infect Dis. 2010; 50: 1258-1267
        • Boeckh M.
        • Berrey M.M.
        • Bowden R.A.
        • Crawford S.W.
        • Balsley J.
        • Corey L.
        Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.
        J Infect Dis. 2001; 184: 350-354
        • Ghosh S.
        • Champlin R.E.
        • Englund J.
        • Giralt S.A.
        • Rolston K.
        • Raad I.
        • et al.
        Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin.
        Bone Marrow Transplant. 2000; 25: 751-755
        • Kimpen J.L.
        Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing.
        Respir Res. 2002; 3: S40-S45
        • Fretzayas A.
        • Moustaki M.
        The challenges of RSV vaccines. Where do we stand?.
        Recent Pat Antiinfect Drug Discov. 2010; 5: 99-107
        • Checchia P.
        Identification and management of severe respiratory syncytial virus.
        Am J Health Syst Pharm. 2008; 65: S7-S12
        • Langley J.M.
        • Smith M.B.
        • LeBlanc J.C.
        • Joudrey H.
        • Ojah C.R.
        • Pianosi P.
        Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076].
        BMC Pediatr. 2005; 5: 7
        • Flores G.
        • Horwitz R.I.
        Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis.
        Pediatrics. 1997; 100: 233-239
        • Schuh S.
        • Coates A.L.
        • Binnie R.
        • Allin T.
        • Goia C.
        • Corey M.
        • et al.
        Efficacy of oral dexamethasone in outpatients with acute bronchiolitis.
        J Pediatr. 2002; 140: 27-32
        • Bentur L.
        • Shoseyov D.
        • Feigenbaum D.
        • Gorichovsky Y.
        • Bibi H.
        Dexamethasone inhalations in RSV bronchiolitis: a double-blind, placebo-controlled study.
        Acta Paediatr. 2005; 94: 866-871
        • McCarthy C.A.
        • Hall C.B.
        Respiratory syncytial virus: concerns and control.
        Pediatr Rev. 2003; 24: 301-309
        • Hess D.R.
        Retrospective studies and chart reviews.
        Respir Care. 2004; 49: 1171-1174
        • Bezerra P.G.
        • Britto M.C.
        • Correia J.B.
        • Duarte Mdo C.
        • Fonceca A.M.
        • Rose K.
        • et al.
        Viral and atypical bacterial detection in acute respiratory infection in children under five years.
        PLoS One. 2011; 6: e18928
        • Stensballe L.G.
        • Kofoed P.E.
        • Nante E.J.
        • Sambo M.
        • Jensen I.P.
        • Aaby P.
        Duration of secretory IgM and IgA antibodies to respiratory syncytial virus in a community study in Guinea-Bissau.
        Acta Paediatr. 2000; 89: 421-426
        • Hall C.B.
        • Weinberg G.A.
        • Iwane M.K.
        • Blumkin A.K.
        • Edwards K.M.
        • Staat M.A.
        • et al.
        The burden of respiratory syncytial virus infection in young children.
        N Engl J Med. 2009; 360: 588-598